Adamis gets US and Japanese patents for Taper DPI

Adamis Pharmaceuticals has announced that the US and Japanese patent offices have approved applications for patents related to the Taper dry powder inhaler, an API-only device that was developed initially by 3M Drug Delivery Systems. Adamis acquired the device from 3M DDS in 2013. US Patent Application No. 13/320,762 and Japanese Patent Application No. 2012-511965, . . . Read more

Study finds that use of triamcinolone nasal spray affects children’s growth

A study published online in Pediatrics finds that children using a triamcinolone nasal spray for allergic rhinitis grew on average 0.44 cm/year less than children using a placebo nasal spray (5.65 cm/year compared to 6.09 cm/year). The year-long study was conducted according to the 2007 FDA guidance on Orally Inhaled and Intranasal Corticosteroids: Evaluation of . . . Read more

GSK launches Arnuity Ellipta and Incruse Ellipta in the US

GlaxoSmithKline has announced that both the Arnuity Ellipta fluticasone furoate DPI and the Incruse Ellipta umeclidinium bromide DPI are now available in the US. Arnuity Ellipta was approved by the FDA in August 2014 for the treatment of asthma. The FDA approved Incruse Ellipta for the treatment of COPD in April 2014. GSK Senior VP . . . Read more